deltatrials
Completed PHASE3 NCT02358031

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor: Merck Sharp & Dohme LLC

Conditions Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer
Interventions 5-FU Carboplatin Cetuximab Cisplatin Pembrolizumab
Updated 23 times since 2017 Last updated: Jul 8, 2025 Started: Mar 19, 2015 Primary completion: Feb 25, 2019 Completion: Jul 19, 2023

A PHASE3 clinical study on Metastatic Head and Neck Cancer and Recurrent Head and Neck Cancer, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 23 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

23 versions recorded

  1. Aug 2025 — Present [monthly]

    Completed PHASE3

  2. Oct 2024 — Aug 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 18 earlier versions

  1. Sep 2023 — Mar 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Dec 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  9. Apr 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Dec 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Apr 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  14. Jun 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  15. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Sep 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE3

  17. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.